Ironwood Pharmaceuticals, Inc. · NASDAQ:IRWD

Ironwood Pharmaceuticals — Q3 2026 Earnings Presentation

19 slides from Ironwood Pharmaceuticals's earnings presentation, Nov 5, 2026

  1. Slide 1: Ironwood Pharmaceuticals Q3 2026 Investor Update

    Ironwood Pharmaceuticals Q3 2026 Investor Update November 5, 2026 1

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about our ability to execute on our mi

  3. Slide 3: Today's agenda

    Today’s agenda • Strategic Priorities and Q3 Business Highlights Tom McCourt, Chief Executive Officer • Q3 LINZESS Performance Update Tammi Gaskins, Chief Commercial Officer • Apraglutide STARS-2 Update Jeffrey Silber, M.D., Chief Medical Officer and Head of Research and Drug Development • Financial

  4. Slide 4: Ironwood raises FY 2026 guidance for second consecutive quarter

    Ironwood raises FY 2026 guidance for second consecutive quarter, driven by continued net sales growth and execution across strategic priorities Q3 2026 Highlights Maximize Advance Deliver Sustained Profits LINZESS Apraglutide and Cash Flow ✓ Expanding STARS-2 confirmatory trial globally ✓ Revised FY

  5. Slide 5: Maximize LINZESS

    Maximize LINZESS The U.S. prescription market leader for adults with Irritable Bowel Syndrome with Constipation (IBS-C) and Chronic Idiopathic Constipation (CIC) 5

  6. Slide 6: LINZESS YTD Q1-Q3 net sales already exceed FY 2025

    LINZESS YTD Q1-Q3 net sales already exceed FY 2025 with strong momentum expected to carry into Q4 EUTRx (total pills) Demand Volume YoY LINZESS Q1-Q3 YTD 2026 U.S. Net Sales Exceed FY 2025 Net Sales ($M) 24 +5% $1,400 FY ‘26 Guidance Millions YTD Y/Y $1.20-1.25B 22 $1,200 20 $1,000 FY $865M YTD $880

  7. Slide 7: Advance Apraglutide

    Advance Apraglutide Glucagon-like peptide-2 (GLP-2) analog for Short Bowel Syndrome with Intestinal Failure (SBS-IF) 7

  8. Slide 8: Confirmatory Phase 3 STARS-2 trial is actively recruiting patients

    Confirmatory Phase 3 STARS-2 trial is actively recruiting patients; Planned U.S. and global site expansion is on track Clinical trial applications Sites planned for Countries across the 100% submitted >100 activation 22 Americas, Europe and Asia Pacific Region • International health authorities • Bu

  9. Slide 9: Apraglutide is the only once-weekly GLP-2 analog with PS volume reduction twice placebo

    Apraglutide is the only once-weekly GLP-2 analog with parenteral support (PS) volume reduction twice that of placebo and sustained improvement over time STARS Phase 3: Primary Endpoint 24 Weeks1 STARS Extend: PS Volume Change thru 184 weeks2 -12.5% P=0.001 STARS: A Multicenter, Double-blind, Randomi

  10. Slide 10: Financial Highlights and 2026 Guidance

    Financial Highlights and 2026 Guidance 10

  11. Slide 11: Ironwood continued to deliver sustained profits in the third quarter

    Ironwood continued to deliver sustained profits in the third quarter $325M $133M LINZESS U.S. Net Sales1,2 Total Ironwood Revenues Q3 2026 LINZESS net sales as reported by AbbVie were Primarily driven by $130 million in U.S. LINZESS $325 million, up 3% year-over-year, driven by 5% demand collaborati

  12. Slide 12: Raising full-year 2026 financial guidance on strength of LINZESS U.S. net sales

    Raising full-year 2026 financial guidance on strength of LINZESS U.S. net sales Previous FY 2026 Revised FY 2026 Guidance Guidance (August 2026) (November 2026) LINZESS U.S. net sales $1.15 to $1.20 billion $1.20 to $1.25 billion Total revenue $460 to $485 million $485 to $510 million Adjusted EBITD

  13. Slide 13: Tammi Gaskins appointed CEO to build on 2026 momentum

    Tammi Gaskins appointed CEO to build on 2026 momentum and lead Ironwood through its next phase of growth 13

  14. Slide 14: Appendix

    APPENDIX 14

  15. Slide 15: Q3 2026 Financial Summary (page 1)

    Q3 2026 Financial Summary Reconciliation of GAAP results to non-GAAP financial measures (page 1) Three Months Ended Nine Months Ended September 30, 2026 September 30, 2026 (000s, except per share (000s, except per share amounts) amounts) GAAP net income1 $ 59,838 $ 151,902 Adjustments: Amortization

  16. Slide 16: Q3 2026 Financial Summary (page 2)

    Q3 2026 Financial Summary Reconciliation of GAAP results to non-GAAP financial measures (page 2) Three Months Ended Nine Months Ended September 30, 2026 September 30, 2026 (000s, except per share (000s, except per share amounts) amounts) GAAP net income per share – diluted1 $ 0.36 $ 0.91 Adjustments

  17. Slide 17: Reconciliation of GAAP net income to adjusted EBITDA

    Q3 2026 Financial Summary Reconciliation of GAAP net income to adjusted EBITDA Three Months Ended Nine Months Ended September 30, 2026 September 30, 2026 (000s) (000s) GAAP net income1 $ 59,838 $ 151,902 Adjustments: Stock-based compensation 4,291 11,180 Restructuring expenses, net - (40) Interest e

  18. Slide 18: Q3 2026 Financial Summary – Total Net Profit

    Q3 2026 Financial Summary – Total Net Profit LINZESS U.S. Brand Collaboration Ironwood & AbbVie Total Net Profit1 Three Months Ended Nine Months Ended September 30, 2026 September 30, 2026 (000s) (000s) LINZESS U.S. net sales as reported by AbbVie2, $ 324,919 $ 879,753 AbbVie & Ironwood commercial c

  19. Slide 19: Q3 2026 Financial Summary – Commercial Profit & Collaboration Revenue

    Q3 2026 Financial Summary – Commercial Profit & Collaboration Revenue LINZESS U.S. Brand Collaboration Commercial Profit & Collaboration Revenue1 Three Months Ended Nine Months Ended September 30, 2026 September 30, 2026 (000s) (000s) LINZESS U.S. net product sales as reported by AbbVie2,3 $ 324,919

Ironwood Pharmaceuticals — Q3 2026 Earnings Presentation on 6ix